Business Segments Takeda Pharmaceutical Company Limited

Equities

Market Closed - Japan Exchange Other stock markets 01:30:00 2025-12-12 EST			5-day change	1st Jan Change
4,448.00 ^JPY	-0.51%		+0.86%	+6.39%

12-07	Takeda, Protagonist Report One-Year Rusfertide Gains in PV trial	MT
12-06	Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Present Longer-Term Data At ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera	CI

See more © MarketScreener.com

See more © MarketScreener.com

Breakdown by Business Segment (JPY)

Fiscal Period: March	2021	2022	2023	2024	2025
Pharmaceutical Products
Pharmaceutical Products	3,198B	3,569B	4,027B	4,264B	4,582B
Total Assets	12,912B	13,178B	13,958B	15,109B	14,248B
Interest Expense	-131B	-122B	-117B	-115B	-130B
Income Tax Expense	-9.94B	72.4B	58.05B	-91.41B	66.94B
CAPEX	-236B	-186B	-634B	-175B	-201B
EBT	366B	303B	375B	52.79B	175B
Gross Profit	-	-	-	-	-
D&A	531B	555B	639B	695B	721B
Operating Income	509B	461B	491B	214B	343B
Net Income	376B	230B	317B	144B	108B
Prescription Drugs	-	-	-	-	-
D&A	-	-	-	-	-
Operating Income	-	-	-	-	-
Non-Prescription Drugs
Consumer Healthcare	-	-	-	-	-
D&A	-	-	-	-	-
Operating Income	-	-	-	-	-
Medicinal Chemicals and Botanical Products
Others	-	-	-	-	-
D&A	-	-	-	-	-
Operating Income	-	-	-	-	-

Geographical breakdown of sales (JPY)

Fiscal Period: March	2021	2022	2023	2024	2025
United States	1,568B	1,714B	2,104B	2,196B	2,380B
Total Assets	6,345B	6,664B	7,560B	8,224B	7,655B
Europe and Canada	666B	739B	843B	967B	1,055B
Total Assets	1,494B	1,515B	799B	861B	800B
Total Assets	-	-	792B	885B	873B
Japan	560B	659B	512B	451B	418B
Total Assets	413B	401B	373B	366B	317B
Latin America	122B	128B	160B	198B	236B
China	-	-	-	-	192B
Other	68.52B	68.94B	95.18B	118B	129B
Total Assets	1,210B	1,278B	1,259B	1,362B	1,330B
Asia (Excluding Japan & China)	-	-	-	-	99.39B
Russia/CIS	57.56B	62.06B	88.43B	72.59B	72.36B
Total Assets	-	-	-	-	-
Asia (Excluding Japan)	156B	197B	225B	261B	-